Literature DB >> 17928981

[Anticonvulsants in the treatment of anxiety--an alternative treatment option?].

P Zwanzger1, D Eser, R Rupprecht.   

Abstract

According to epidemiological studies anxiety disorders are among the most frequent psychiatric disorders. Depending on the diagnosis and severity, both cognitive behaviour therapy and pharmacological approaches are applied. In today's drug therapy antidepressants are the standard first-line treatment for most anxiety disorders, and enzodiazepines for the treatment of acute anxiety states. However, many patients do not respond to the first drug prescribed, prove to have conditions that are resistant to therapy or complain of side effects. There is therefore still a need for new medicamentous treatment strategies. There are numerous studies suggesting that anticonvulsants also have potentially anxiolytic properties and might therefore be an alternative treatment option in anxiety syndromes. This article gives an overview of investigations to date on the effects of various anticonvulsants in panic disorder, generalized anxiety disorder and social phobia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928981     DOI: 10.1007/s00115-007-2361-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Treatment of social phobia with gabapentin: a placebo-controlled study.

Authors:  A C Pande; J R Davidson; J W Jefferson; C A Janney; D J Katzelnick; R H Weisler; J H Greist; S M Sutherland
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

3.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 4.  Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Authors:  Peter Zwanzger; Rainer Rupprecht
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

5.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

6.  An open trial of topiramate in the treatment of generalized social phobia.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Jonathan Oakman; Mark Bennett
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

7.  Unmet needs in the treatment of anxiety disorders.

Authors:  Mark H Pollack
Journal:  Psychopharmacol Bull       Date:  2004

8.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05

9.  An open-label study of levetiracetam for the treatment of social anxiety disorder.

Authors:  Naomi M Simon; John J Worthington; Alicia C Doyle; Elizabeth A Hoge; Gustavo Kinrys; Diana Fischmann; Nathaniel Link; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2004-09       Impact factor: 4.384

10.  Panic disorder: treatment with valproate.

Authors:  C L Woodman; R Noyes
Journal:  J Clin Psychiatry       Date:  1994-04       Impact factor: 4.384

View more
  1 in total

1.  Varying uses of anticonvulsant medications.

Authors:  Elisa Cascade; Amir H Kalali; Richard H Weisler
Journal:  Psychiatry (Edgmont)       Date:  2008-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.